Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 5/20 | 0.34 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.33 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.33 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22438962 | 0.91 | IDO1 (0.40) | IDO1CYP2C9PTGER4PTGDRBTK | |
| SCHEMBL23908272 | 0.86 | IDO1 (0.52) | IDO1CYP2C9PDE2A | |
| SCHEMBL22438885 | 0.77 | IDO1 (0.52) | IDO1CYP2C9PTGER4PTGDRBTK | |
| SCHEMBL22438913 | 0.76 | IDO1 (0.54) | IDO1CYP2C9PTGER4PTGDRPDE2A | |
| SCHEMBL20972015 | 0.76 | IDO1 (0.55) | IDO1CYP2C9 | |
| SCHEMBL30636537 | 0.75 | IDO1 (0.47) | IDO1CYP2C9 | |
| SCHEMBL20972064 | 0.75 | IDO1 (0.47) | IDO1CYP2C9 | |
| SCHEMBL22439174 | 0.75 | IDO1 (0.54) | IDO1CYP2C9 | |
| SCHEMBL20972076 | 0.75 | IDO1 (0.76) | IDO1CYP2C9 | |
| SCHEMBL20972220 | 0.74 | IDO1 (0.46) | IDO1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317091-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317091-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | IDO1 1/4885CYP2C9 915/4885BDKRB1 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.